We believe that our conclusions regarding the prevalence of ErbB2-positive breast cancer and ErbB2 assessment methods in Asia are strengthened by the use of data from 22 studies involving more than 14,000 patients in 7 Asian countries that vary in ethnicity, size, and economic status. This evidence concerns the gene ERBB2 and breast carcinoma.